lexiara

2.

The application shall be accompanied by the following particulars and documents: name or corporate name and permanent address of the sponsor; active ingredients of the medicinal product; proposed therapeutic indication; justification that the criteria laid down in Article 3(1) are met and a description of the stage of development, including the indications expected.

· All articles ·

Source: EUR-Lex (Cellar) · retrieved 2026-11-21 · Text as adopted (Official Journal); later amendments are not incorporated in this text.